arrow
J

Ja Hyeon Ku

Seoul National University Hospital
H指数:46
被引数:9,765

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

ctDNA指导下的辅助阿特珠单抗治疗在肌肉浸润性膀胱癌中的应用

2025-10-0110
PRE
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

TAR-200联合西特雷利单抗与西特雷利单抗单药治疗作为不适合或拒绝新辅助顺铂为基础化疗的肌层浸润性膀胱癌患者的新辅助治疗(SunRISe-4):一项随机、开放标签Ⅱ期试验的期中分析

2025-08-270
PRE
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

作者更正: Sasanlimab加BCG在BCG幼稚,高危非肌层浸润性膀胱癌中的应用: 随机3期CREST试验

2025-07-210
OA
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Shore ND,Powles TB,Bedke J 等。Sasanlimab 联合 BCG 治疗 BCG-naive、高风险非肌层浸润性膀胱癌:随机 III 期 CREST 试验。Nat Med. 2025;31(8):2806-2814.

2025-05-310
OAAI
Preoperative smoking and robot-assisted radical cystectomy outcomes & complications in multicenter KORARC database

多中心KORARC数据库中的术前吸烟和机器人辅助根治性膀胱切除术结果和并发症

2024-05-080
OAAI
A dietary commensal microbe enhances antitumor immunity by activating tumor macrophages to sequester iron
2024-04-254
PRE
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

CREST: sasanlimab和卡介苗对卡介苗-幼稚高危非肌肉浸润性膀胱癌患者的III期研究

2024-01-086
OA
First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non emuscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
2023-10-0110
OA